Cardiomyopathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are older than 18 years of age
- You have been diagnosed with light chain (AL) amyloidosis confirmed through standard blood, urine, or tissue tests
- If you are traveling from out of town and your biopsy results are still pending, you may be able to start the study before results are confirmed (confirm with trial site)
- You are willing and able to give your consent to participate
- For the "Remission" group only: Your blood disease has been in deep remission for more than 1 year, with very low abnormal protein levels in your blood
- For the "Active with exercise" group only: You are able to ride a stationary bicycle while lying on your back
- For the "Early heart involvement" group only: Your heart wall thickness and heart function are either normal, or your heart wall is slightly thickened but your heart blood markers are normal, based on a recent heart ultrasound
- For the "Multiple myeloma control" group only: You have been diagnosed with multiple myeloma but do NOT have amyloidosis
- For the "Heart failure control" group only: You have been diagnosed with heart failure but do NOT have amyloidosis
- For the "Active heart involvement" group only: You have abnormal heart stress marker levels in your blood (confirm with trial site for specific values)
Who may not be able to join:
- Your blood pressure or circulation is currently unstable
- Your heart failure is severe enough that you cannot lie flat for at least 1 hour
- You have a heart condition unrelated to amyloidosis or blocked arteries, such as a leaky heart valve or an enlarged heart from another cause
- You have significantly blocked heart arteries (more than 50% blockage in any area)
- You have severe claustrophobia that cannot be managed even with calming medication
- You have a metal implant in your body, such as a pacemaker or defibrillator, that is not safe for MRI scans (heart failure control group participants with MRI-safe devices may still be eligible — confirm with trial site)
- Your kidneys are not working well enough (based on a blood test taken within 14 days of each MRI scan) — though heart failure control participants with poor kidney function may still have an MRI without the contrast dye
- You are currently on kidney dialysis
- You are pregnant (a urine pregnancy test will be done before certain scans if you could become pregnant)
- You have a known allergy to any of the imaging agents used in this study (confirm with trial site for specific agent names)
- For the "Active heart involvement" group only: You are unable to return to the study hospital for check-ups at 6 and 12 months
- For the "Active with exercise" group only: You are unable to exercise or return to the study hospital for scans at the start of the study and at 6 months
- For the "Early heart involvement" group only: You are unable to return to the study hospital for a 12-month check-up
- For the gut microbiome part of the study only: You have certain other heart, bowel, or infectious conditions, have taken antibiotics or certain other medications recently, have had bowel surgery or colon cancer, have received chemotherapy, are pregnant, or are unable to mail a stool sample in the required timeframe (confirm with trial site for full details)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Sharmila Dorbala, MD, Brigham and Women's Hospital (AHA and NIH Studies)
Phone: 617-732-6290
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in F-18 florbetapir myocardial retention index from baseline to 6 months and 12 months; Change in Serum oxidative stress markers from baseline to 6 months and 12 months; Change in Myocardial oxidative metabolism markers from baseline to 6 months; Change in Magnetic resonance imaging markers from baseline to 6 months and 12 months
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.